<DOC>
	<DOCNO>NCT02929394</DOCNO>
	<brief_summary>Maintenance therapy trabectedin versus observation first line treatment doxorubicin patient advance metastatic soft tissue sarcoma . This prospective , multicenter , randomize , open label Phase III trial investigate whether maintenance treatment trabectedin , compare observational approach , prolong progression-free survival patient advance , inoperable and/or metastatic STS response stabilisation first line treatment doxorubicin .</brief_summary>
	<brief_title>Trabectedin Maintenance Post 1st-line STS</brief_title>
	<detailed_description>Progression free survival estimate Kaplan-Meier method . The median survival time associate 95 % non-parametric CI provide . Rates 3 month interval estimate use log-log transformation Kaplan-Meier estimate standard deviation Kaplan Meier estimate base Greenwood formula . For primary analysis , PFS randomization compare two arm use score test Cox proportional hazard model adjust histology ( stratification factor ) . The corresponding estimate treatment effect ( hazard ratio ) 95 % CI provide . Secondary analysis include : - primary comparison PFS repeat use method interval-censored data adjust deviation plan image schedule , . - mentioned analysis perform PFS measure date start firstline doxorubicin treatment . Overall survival time second progression ( PFS2 ) measure randomization start firstline doxorubicin treatment estimate Kaplan-Meier method . The median time associate 95 % non-parametric CI calculate . Rates 3 month interval estimate use log-log transformation Kaplan-Meier estimate standard deviation Kaplan Meier estimate base Greenwood formula . They compare two arm use adjusted Cox proportional hazard model ; correspond estimate hazard ratio 95 % CI provide . The mentioned PFS2 comparison also repeat use method interval-censored data . The adverse event relate treatment ( exclude declare reasonably possibly related treatment , include relationship assessable ) describe safety population . Worst grade AEs tabulate . Whenever CTCAE code exists , grade display accord system , otherwise value cod three category low limit normal ( LLN ) , within normal range , upper limit normal ( ULN ) , deem appropriate . The percentage patient present severe treatment-related AE ( grade ≥ 3 ) , patient report died toxicity patient stop treatment due toxicity calculate 95 % confidence interval present .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Histologically prove locally advanced metastatic high grade STS ( exclude histology insensitive chemotherapy ASPS , PECOMA subtypes ) Nonprogressive disease ( CR , PR SD accord RECIST 1.1 ) 6 cycle firstline chemotherapy doxorubicin advance and/or metastatic malignant STS . Interval last dose doxorubicin start treatment maximum 6 week . Prior neoadjuvant adjuvant nonanthracyclinechemotherapy allow , provide disease progress neoadjuvant and/or adjuvant therapy within 12 week completion perioperative treatment . Representative formalin fix , paraffin embed tumor block 10 unstained tissue slide , either primary tumor metastatic lesion , must available histological central review . Histological central review require treatment start mandatory send unstained tumor slide ( block optional ) time study entry . Local histopathological diagnosis accept entry trial . Age 18 year old WHO performance status ≤ 1 Adequate bone marrow , liver renal function coagulation parameter : neutrophil ≥ 1.5 x 109/L ; hemoglobin ≥ 9 g/dL ( ≥ 5.6 mmol/L ) . Blood transfusion administration hematopoietic growth factor allow achieve baseline value ; platelet ≥ 100 x 109/L ; Total bilirubin ≤ ULN ; Albumin &gt; 30g/L SGPT/ALT SGOT/AST ≤ 2.5 x ULN patient liver metastasis patient Gilbert syndrome bilirubin ≤ ULN ; Creatine phosphokinase ( CPK ) ≤ 2.5 x ULN ; Alkaline phosphatase ≤ 2.5 x ULN ( consider hepatic isoenzymes 5nucleotidase gamma glutamyl transpeptidase ( GGT ) , elevation could osseous origin ) ; Creatinine clearance/eGFR &gt; 30mL/minmin per local standard method Normal cardiac function ( LVEF assess MUGA ECHO within normal range institution ) , normal 12 lead ECG ( without clinically significant abnormality ) . The follow unstable cardiac condition allow : Congestive heart failure Angina pectoris Myocardial infarction within 1 year registration/randomization Uncontrolled arterial hypertension define blood pressure ≥ 150/100 mm Hg despite optimal medical therapy Arrhythmias clinically significant No prior exposure trabectedin Recovery toxicity ( Grade 1 , except alopecia ) No active uncontrolled infection serious illness medical condition , include history chronic alcohol abuse , hepatitis , HIV and/or cirrhosis . No active brain metastasis ( e.g . stable &lt; 4 week , adequate previous treatment radiotherapy , symptomatic , require treatment anticonvulsant ; dexamethasone therapy allow administer stable dose least one month randomization ) No history , within past five year , malignancy soft tissue sarcoma ( except : basal squamous cell carcinoma skin , situ carcinoma cervix , resect incidental prostate cancer stag pT2 Gleason Score 6 postoperative PSA &lt; 0.5 ng/ml ) . Patients history malignancy diseasefree 5 year eligible . Women child bear potential ( WOCBP ) must negative serum pregnancy test within 72 hour prior first dose study treatment . Patients childbearing / reproductive potential use adequate birth control measure , define investigator , study treatment period least 3 month last study treatment . A highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly . Female patient breast feed discontinue nursing prior first dose study treatment.and 3 month last study treatment . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial Before patient registration/randomization , write informed consent must give accord ICH/GCP , national/local regulation . Important note : All eligibility criterion must adhere , case deviation discussion Headquarters study coordinator mandatory .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Histologically prove locally advanced metastatic high grade STS ( exclude histology insensitive chemotherapy ASPS , PECOMA subtypes )</keyword>
</DOC>